To address these challenges, the present report investigated GSK-3β inhibitor, 9-ING-41, rather than PD-1/PD-L1-targeted ICI to pharmacologically inhibit checkpoint upregulation within the tumor milieu and combat T-cell exhaustion in combination with multifunctional HY-oAd. The gene discussed is GSK3B; the disease is neoplasm.